Yong G. Lee

Ansan, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Combining sorafenib with spermine and sphingosine synergistically enhances anticancer efficacy by modulating metabolic pathways and gut microbiome in hepatocellular carcinoma.

Combining sorafenib with spermine and sphingosine synergistically enhances anticancer efficacy by modulating metabolic pathways and gut microbiome in hepatocellular carcinoma.

Journal: International journal of biological sciences

Published: June 03, 2025

Hidden Partner of Immunity: Microbiome as an Innovative Companion in Immunotherapy.

Hidden Partner of Immunity: Microbiome as an Innovative Companion in Immunotherapy.

Journal: International journal of molecular sciences

Published: December 16, 2024

CD5 deletion enhances the antitumor activity of adoptive T cell therapies.

CD5 deletion enhances the antitumor activity of adoptive T cell therapies.

Journal: Science immunology

Published: July 19, 2024

Development of New Diffuse Large B Cell Lymphoma Mouse Models.

Development of New Diffuse Large B Cell Lymphoma Mouse Models.

Journal: Cancers

Published: June 26, 2024

Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study.

Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study.

Journal: Molecular cancer

Published: August 25, 2023

The BTLA-HVEM axis restricts CAR T cell efficacy in cancer.

The BTLA-HVEM axis restricts CAR T cell efficacy in cancer.

Journal: Nature immunology

Published: May 08, 2023

Streamlined measurement of chimeric antigen receptor T-cell concentration, size, viability and two-color phenotyping during manufacturing.

Streamlined measurement of chimeric antigen receptor T-cell concentration, size, viability and two-color phenotyping during manufacturing.

Journal: Cytotherapy

Published: April 30, 2023

Apoptosis: a Janus bifrons in T-cell immunotherapy.

Apoptosis: a Janus bifrons in T-cell immunotherapy.

Journal: Journal for immunotherapy of cancer

Published: February 04, 2023

Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy.

Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: April 01, 2022

Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer.

Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer.

Journal: Cancer discovery

Published: August 27, 2021

The current landscape of single-cell transcriptomics for cancer immunotherapy.

The current landscape of single-cell transcriptomics for cancer immunotherapy.

Journal: The Journal of experimental medicine

Published: October 07, 2020

Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction.

Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction.

Journal: Cancer discovery

Published: July 12, 2019

Showing 1-12 of 14

Last Updated: 09/26/2026